| Literature DB >> 30947097 |
Elwira Chrobak1, Monika Kadela-Tomanek2, Ewa Bębenek2, Krzysztof Marciniec2, Joanna Wietrzyk3, Justyna Trynda3, Bartosz Pawełczak4, Joachim Kusz5, Janusz Kasperczyk6, Ewa Chodurek7, Piotr Paduszyński7, Stanisław Boryczka2.
Abstract
Betulin derivatives exhibit an antiproliferative activity and have been tested for many cancer cell lines. This paper describes a new series of 3-phosphate derivatives of betulin bearing different substituents at C28 position. The synthesized compounds were tested in vitro for their antiproliferative effect against human leukemia (MV-4-11 and CCRF/CEM), lung carcinoma (A549), prostate cancer (DU 145), melanoma (Hs 294T) cell lines, and murine leukemia P388. To explore the possible mechanism of anticancer activity for the most in vitro active compounds (4, 5, 7 and 8) and betulin, molecular docking was performed to the binding sites of potential anticancer targets, described for the various triterpene derivatives, including topoisomerase I and II, epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGFR), transcription factor NF-κB, anti-apoptotic protein Bcl-2 and peroxisome proliferator-activated receptor (PPARγ). According to the results of the docking, the best fit to the binding pocket of PPARγ was shown by compound 4.Entities:
Keywords: Anticancer; Betulin; Crystal structure; Molecular docking; Phosphate
Year: 2019 PMID: 30947097 DOI: 10.1016/j.bioorg.2019.03.060
Source DB: PubMed Journal: Bioorg Chem ISSN: 0045-2068 Impact factor: 5.275